AR126691A1 - RNAi COMPOSITIONS AND METHODS TO SILENCE THE ANGIOTENSINOGEN (AGT) GENE - Google Patents
RNAi COMPOSITIONS AND METHODS TO SILENCE THE ANGIOTENSINOGEN (AGT) GENEInfo
- Publication number
- AR126691A1 AR126691A1 ARP220102078A ARP220102078A AR126691A1 AR 126691 A1 AR126691 A1 AR 126691A1 AR P220102078 A ARP220102078 A AR P220102078A AR P220102078 A ARP220102078 A AR P220102078A AR 126691 A1 AR126691 A1 AR 126691A1
- Authority
- AR
- Argentina
- Prior art keywords
- agt
- gene
- agent
- hsrna
- angiotensinogen
- Prior art date
Links
- 102000004881 Angiotensinogen Human genes 0.000 title abstract 12
- 108090001067 Angiotensinogen Proteins 0.000 title abstract 12
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 108091030071 RNAI Proteins 0.000 title abstract 3
- 230000009368 gene silencing by RNA Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 11
- 230000000692 anti-sense effect Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 101150070360 Agt gene Proteins 0.000 abstract 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 abstract 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108091081021 Sense strand Proteins 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se relaciona con agentes de ARNi, por ejemplo, agentes de ARN de hebra doble (ARNhd), dirigidos a un gen de angiotensinógeno (AGT). La invención también se relaciona con métodos para usar dichos agentes de ARNi para inhibir la expresión de un gen AGT gene y métodos para prevenir y tratar un trastorno asociado con el AGT, por ejemplo, hipertensión. Reivindicación 1: Un agente de ácido ribonucleico de hebra doble (ARNhd) para inhibir la expresión del gen de angiotensinógeno (AGT) en una célula, caracterizado porque el agente de ARNhd comprende una hebra sentido y una hebra antisentido que forman una región de hebra doble, en donde la hebra antisentido comprende una región de complementariedad con un ARNm que codifica AGT, y en donde la región de complementariedad comprende por lo menos 15 nucleótidos contiguos que difieren en no más de 3 nucleótidos de cualquiera de las secuencias de nucleótidos antisentido de cualquiera de las Tablas 2 - 7. Reivindicación 43: Una célula, caracterizada porque contiene el agente de ARNhd de cualquiera de las reivindicaciones 1 - 42. Reivindicación 44: Una composición farmacéutica para inhibir la expresión de un gen que codifica el gen de angiotensinógeno (AGT) caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 - 42 y un vehículo farmacéuticamente aceptable. Reivindicación 50: Un método para inhibir la expresión de un gen de angiotensinógeno (AGT) en una célula, caracterizado porque dicho método comprende poner la célula en contacto con el agente de ARNhd de cualquiera de las reivindicaciones 1 - 42, o la composición farmacéutica de cualquiera de las reivindicaciones 44 - 49, para de esa manera inhibir la expresión del gen AGT en la célula. Reivindicación 79: Un vial, caracterizado porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 - 42 o la composición farmacéutica de cualquiera de las reivindicaciones 44 - 49. Reivindicación 80: Una jeringa, caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 - 42 o la composición farmacéutica de cualquiera de las reivindicaciones 44 - 49. Reivindicación 81: Un complejo de silenciamiento inducido por ARN (RISC), caracterizado porque comprende una hebra antisentido de cualquiera de los agentes de ARNhd de las reivindicaciones 1 - 42.The present invention relates to RNAi agents, for example, double-stranded RNA (dsRNA) agents, targeting an angiotensinogen (AGT) gene. The invention also relates to methods of using such RNAi agents to inhibit the expression of an AGT gene and methods of preventing and treating a disorder associated with AGT, for example, hypertension. Claim 1: A double-stranded ribonucleic acid (hdRNA) agent for inhibiting the expression of the angiotensinogen (AGT) gene in a cell, characterized in that the dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region , wherein the antisense strand comprises a region of complementarity with an mRNA encoding AGT, and wherein the region of complementarity comprises at least 15 contiguous nucleotides that differ by no more than 3 nucleotides from any of the antisense nucleotide sequences of either of Tables 2 - 7. Claim 43: A cell, characterized in that it contains the hsRNA agent of any of claims 1 - 42. Claim 44: A pharmaceutical composition for inhibiting the expression of a gene encoding the angiotensinogen (AGT) gene ) characterized in that it comprises the hsRNA agent of any of claims 1-42 and a pharmaceutically acceptable carrier. Claim 50: A method for inhibiting the expression of an angiotensinogen (AGT) gene in a cell, characterized in that said method comprises contacting the cell with the hsRNA agent of any of claims 1 - 42, or the pharmaceutical composition of any of claims 44 - 49, to thereby inhibit the expression of the AGT gene in the cell. Claim 79: A vial, characterized in that it comprises the hsRNA agent of any of claims 1 - 42 or the pharmaceutical composition of any of claims 44 - 49. Claim 80: A syringe, characterized in that it comprises the hsRNA agent of any of claims 1 - 42 or the pharmaceutical composition of any of claims 44 - 49. Claim 81: An RNA-induced silencing complex (RISC), characterized in that it comprises an antisense strand of any of the hsRNA agents of claims 1 - 42.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063272769P | 2020-10-28 | 2020-10-28 | |
| US202163229085P | 2021-08-04 | 2021-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126691A1 true AR126691A1 (en) | 2023-11-01 |
Family
ID=89061563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102078A AR126691A1 (en) | 2020-10-28 | 2022-08-03 | RNAi COMPOSITIONS AND METHODS TO SILENCE THE ANGIOTENSINOGEN (AGT) GENE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126691A1 (en) |
-
2022
- 2022-08-03 AR ARP220102078A patent/AR126691A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002870A1 (en) | Arni compositions against angiotensinogen (agt) and methods for their use | |
| EP2222848B1 (en) | Novel sirna structure for minimizing off-target effects and relaxing saturation of rnai machinery and the use thereof | |
| PE20241132A1 (en) | ARNI COMPOSITIONS AND METHODS TO SILENCE ANGIOTENSINOGEN (AGT) | |
| EP2021507A4 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
| PE20230179A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DISORDER ASSOCIATED WITH ANGIOTENSINOGEN (AGT) | |
| PE20241933A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | |
| JP2017528441A5 (en) | ||
| AR126691A1 (en) | RNAi COMPOSITIONS AND METHODS TO SILENCE THE ANGIOTENSINOGEN (AGT) GENE | |
| AR126771A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE | |
| AR125230A1 (en) | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE | |
| AR079649A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18 | |
| AR124636A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF a-1 ANTITRYPSIN | |
| AR126675A1 (en) | COMPOSITIONS OF RNAi AGAINST TRANSTHYRRETIN (TTR) AND THEIR METHODS OF USE | |
| AR130702A1 (en) | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USING THE SAME | |
| AR126536A1 (en) | COMPOSITIONS OF RNAi DIRECTED AGAINST b-CATENIN (CTNNB1) AND THEIR METHODS OF USE | |
| AR125021A1 (en) | RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE | |
| AR126070A1 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) | |
| AR127472A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTIN (HTT) AND THEIR METHODS OF USE | |
| AR124052A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR V COAGULATION (F5) AND METHODS OF USE THEREOF | |
| AR125019A1 (en) | RNAi COMPOSITIONS AGAINST KETOHEXOKINASE (KHK) AND THEIR METHODS OF USE | |
| CN101173275A (en) | Small interfering RNA for inhibiting SARS coronavirus M protein gene expression and its coding gene and application | |
| AR120979A1 (en) | RNAi COMPOSITIONS CONTAINING A PATATIN-LIKE PHOSPHOLIPASE 3 (PNPLA3) DOMAIN AND THEIR METHODS OF USE | |
| AR126265A1 (en) | COMPOSITIONS AND METHODS TO SILENCE MYOC EXPRESSION | |
| AR126271A1 (en) | LEUCINE-RICH REPEATED KINASE 2 (LRRK2) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | |
| US12042509B2 (en) | Prekallikrein-modulating compositions and methods of use thereof |
